Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New cellular flaw found in some virulent breast cancers

18.01.2006


Overactive growth controller could become drug target



Researchers at Dana-Farber Cancer Institute have identified a molecular interaction that triggers a particularly aggressive form of breast cancer, and suggest that attacking this target with selective drugs might improve treatment.

In the January issue of Cancer Cell, a team led by Qunyan Yu, MD, and Peter Sicinski, MD, PhD, of Dana-Farber report that the interaction of a certain mutated oncogene and the newly described growth control flaw is seen in about 10 percent of breast cancers – and the deadliest ones.


The cancer results from a cascade of molecular events. The overproduction of a common protein, cyclin D1, hyperstimulates a growth switch, CDK4 kinase, causing it to unleash a virulent proliferation of cancer cells and creating a tumor with a very poor prognosis.

"The development of cancer drugs like Gleevec and Iressa have shown that it is possible to block the action of kinases," said Sicinski, "so we hope that these findings will stimulate interest in developing drugs to block CDK4 as a targeted approach to treating this very aggressive cancer."

Breast cancers composed of cells that contain both the overactive cyclin D1- CDK4 switch and a mutated cancer-causing gene ErbB-2 (also known as HER2) are extremely difficult to treat. In one recent study, the seven-year survival rate for women with this subgroup of breast cancers was only about 13 percent.

Clinicians have had some recent success in treating breast cancers with a mutated ErbB-2 gene, which are also referred to as being HER2-positive. The targeted therapy Herceptin blocks the mutation, improving the outlook for such patients, though it doesn’t work in all cases. Sicinski said that a CDK4 inhibitor might be used in combination with Herceptin to provide further benefit in these patients.

If a drug to block CDK4 proved feasible, Sicinski said, it may be possible to test women’s breast tumors for the presence of the overactive kinase, and then treat those patients with the inhibitor. "We are going to see in the next five years a movement away from treating all tumors with the same drugs, and instead match specific drugs to tumors based on their molecular characteristics," said Sicinski, who is also an associate professor of pathology at Harvard Medical School.

Cyclin D1 is one of a family of proteins that help regulate a cell’s passage through its cycle of rest and growth. Overabundance of cyclin D1 has been observed in many cancers. For a number of years, Sicinski’s laboratory has carried out a series of experiments to determine whether the protein has an important normal function, or whether it could be blocked by designer drugs to treat breast cancer without harming the patient.

Previously, mice engineered to lack cyclin D1 were found to be highly resistant to certain breast cancers, and other experiments showed that mice in which the cyclin D1 gene had been inactivated developed into more or less normal adults.

However, said Sicinski, it is difficult to design a drug to neutralize the action of a protein like cyclin D1. In the most recent experiments, the research team’s objective was to determine precisely which of cyclin D1’s several different functions was responsible for causing breast cancer.

By creating laboratory mice with different combinations of genes present or missing, the researchers were able to isolate the various cyclin D1 activities. They demonstrated that cyclin D1’s ability to activate CDK4 kinase activity is what causes the aggressive cancers, and that this same activity is required for the cancer to continue to grow.

Additional experiments reported in another Cancer Cell paper found that bioengineered mice in which cyclin D1 could not activate CDK4 kinase were developmentally normal and highly resistant to ErbB-2-caused breast cancers, demonstrating that blocking CDK4 was not harmful to the mice. That research was carried out by scientists at Tufts-New England Medical Center, Harvard Medical School, and Massachusetts Eye and Ear Infirmary, together with Sicinski.

The identification of the cyclin D1-CDK4 kinase pathway is important and could pave the way to new therapies, says Sicinski, adding that while it would be difficult to design a drug to inhibit the action of a protein like cyclin D1, blocking a kinase is significantly easier.

Bill Schaller | EurekAlert!
Further information:
http://www.dfci.harvard.edu
http://www.dana-farber.org

More articles from Life Sciences:

nachricht New risk factors for anxiety disorders
24.02.2017 | Julius-Maximilians-Universität Würzburg

nachricht Stingless bees have their nests protected by soldiers
24.02.2017 | Johannes Gutenberg-Universität Mainz

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Stingless bees have their nests protected by soldiers

24.02.2017 | Life Sciences

New risk factors for anxiety disorders

24.02.2017 | Life Sciences

MWC 2017: 5G Capital Berlin

24.02.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>